These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35294527)

  • 1. Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis.
    Penel N; Bonvalot S; Bimbai AM; Meurgey A; Le Loarer F; Salas S; Piperno-Neumann S; Chevreau C; Boudou-Rouquette P; Dubray-Longeras P; Kurtz JE; Guillemet C; Bompas E; Italiano A; Le Cesne A; Orbach D; Thery J; Le Deley MC; Blay JY; Mir O
    Clin Cancer Res; 2022 Sep; 28(18):4105-4111. PubMed ID: 35294527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only: A Meta-analysis of Individual Patient Data.
    Timbergen MJM; Colombo C; Renckens M; Kim HS; Rosmalen JV; Salas S; Mullen JT; Colombo P; Nishida Y; Wiemer EAC; Verhoef C; Sleijfer S; Gronchi A; Grünhagen DJ
    Ann Surg; 2021 Jun; 273(6):1094-1101. PubMed ID: 31804402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.
    Colombo C; Miceli R; Lazar AJ; Perrone F; Pollock RE; Le Cesne A; Hartgrink HH; Cleton-Jansen AM; Domont J; Bovée JV; Bonvalot S; Lev D; Gronchi A
    Cancer; 2013 Oct; 119(20):3696-702. PubMed ID: 23913621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis.
    van Broekhoven DL; Verhoef C; Grünhagen DJ; van Gorp JM; den Bakker MA; Hinrichs JW; de Voijs CM; van Dalen T
    Ann Surg Oncol; 2015 May; 22(5):1464-70. PubMed ID: 25341748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features of 70 desmoid-type fibromatoses confirmed by β-catenin immunohistochemical staining and CTNNB1 mutation analysis.
    An J; Woo HY; Lee Y; Kim HS; Jeong J; Kim SK
    PLoS One; 2021; 16(4):e0250619. PubMed ID: 33914771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
    Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
    Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of
    Mir O; Honoré C; Chamseddine AN; Dômont J; Dumont SN; Cavalcanti A; Faron M; Rimareix F; Haddag-Miliani L; Le Péchoux C; Levy A; Court C; Briand S; Fadel E; Mercier O; Bayle A; Brunet A; Ngo C; Rouleau E; Adam J; Le Cesne A
    Clin Cancer Res; 2020 Dec; 26(23):6277-6283. PubMed ID: 32873570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
    Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
    Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
    Norkowski E; Masliah-Planchon J; Le Guellec S; Trassard M; Courrèges JB; Charron-Barra C; Terrier P; Bonvalot S; Coindre JM; Laé M
    Am J Surg Pathol; 2020 Sep; 44(9):1266-1273. PubMed ID: 32590455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathological and molecular genetic features of neuromuscular choristoma-associated desmoid type fibromatosis].
    Dong RF; Guo W; Li N; Wang ZY; Sun XQ; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):685-690. PubMed ID: 38955699
    [No Abstract]   [Full Text] [Related]  

  • 11. Does the Addition of Mutations of CTNNB1 S45F to Clinical Factors Allow Prediction of Local Recurrence in Patients With a Desmoid Tumor? A Local Recurrence Risk Model.
    Pinto FFE; Mello CAL; Nakagawa SA; Chung WT; Torrezan GT; Barros BDF; Cunha IW; Calsavara VF; Carraro DM; Lopes A
    Clin Orthop Relat Res; 2023 Oct; 481(10):1978-1989. PubMed ID: 37104792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
    Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
    PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
    Sakai T; Nishida Y; Hamada S; Koike H; Ikuta K; Ota T; Ishiguro N
    Diagn Pathol; 2017 Aug; 12(1):66. PubMed ID: 28851389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis.
    Colombo C; Fiore M; Grignani G; Tolomeo F; Merlini A; Palassini E; Collini P; Stacchiotti S; Casali PG; Perrone F; Mariani L; Gronchi A
    Clin Cancer Res; 2022 Sep; 28(18):4027-4032. PubMed ID: 35247923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Droplet Digital PCR (ddPCR) as a Novel Technology in Detecting CTNNB1 Mutations in Desmoid Fibromatosis.
    Gandhi J; Kao E; Wu Y; Mantilla JG; Ricciotti RW; Bandhlish A; Liu YJ; Chen EY
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):662-667. PubMed ID: 36227098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of
    Guo L; Wang X; Xu B; Lang R; Hu B
    Future Oncol; 2021 Feb; 17(4):435-442. PubMed ID: 33397129
    [No Abstract]   [Full Text] [Related]  

  • 17. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.
    Nathenson MJ; Hu J; Ratan R; Somaiah N; Hsu R; DeMaria PJ; Catoe HW; Pang A; Subhawong TK; Amini B; Sweet K; Feister K; Malik K; Jagannathan J; Braschi-Amirfarzan M; Sheren J; Caldas Y; Moreno Tellez C; Rosenberg AE; Lazar AJ; Maki RG; Benedetto P; Cohen J; Trent JC; Ravi V; Patel S; Wilky BA
    Clin Cancer Res; 2022 Sep; 28(18):4092-4104. PubMed ID: 35180772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.
    Koike H; Nishida Y; Kohno K; Shimoyama Y; Motoi T; Hamada S; Kawai A; Ogose A; Ozaki T; Kunisada T; Matsumoto Y; Matsunobu T; Ae K; Gokita T; Sakai T; Shimizu K; Ishiguro N
    Hum Pathol; 2019 Feb; 84():155-163. PubMed ID: 30292627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTNNB1 Mutations and Estrogen Receptor Expression in Neuromuscular Choristoma and Its Associated Fibromatosis.
    Carter JM; Howe BM; Hawse JR; Giannini C; Spinner RJ; Fritchie KJ
    Am J Surg Pathol; 2016 Oct; 40(10):1368-74. PubMed ID: 27259010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: A multicenter study in Japan.
    Nishida Y; Hamada S; Kawai A; Kunisada T; Ogose A; Matsumoto Y; Ae K; Toguchida J; Ozaki T; Hirakawa A; Motoi T; Sakai T; Kobayashi E; Gokita T; Okamoto T; Matsunobu T; Shimizu K; Koike H
    Cancer Sci; 2020 Aug; 111(8):2935-2942. PubMed ID: 32539220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.